Mutual funds are subject to market risk. Read all scheme documents carefully.
The fund is rated 1 star. Investment selection within each asset type and balance between returns and downside risk provided some support. Investment selection within each industry was the main limitation and did not provide enough support for a higher rating. Above-average fund size of Rs 9,166.4 crore was a minor drawback.
This fund has a ok track record with Asset Selection/Timing, a bad track record with Stock Selection/Timing. It is important to note, however, that this fund has a 9166.399 AUM and a 1.83 expense ratio. Considering all these factors, we have rated this fund as 1.0 star.
Our score weighs long-term performance, risk and consistency — not just past returns.
As of 20 Nov 2026
As of 31 Oct 2026
Long term capital growth. Investment in equity and equity related Securities of pharma & other associated companies.
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Exit load of 1% if redeemed within 1 month.

As of 31 Oct 2026
| Holding | % of fund | Value | Shares |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 11.55% | ₹1,049.97 Cr | 59,06,349 |
| Divi's Laboratories Ltd. | 6.73% | ₹611.99 Cr | 6,25,754 |
| Cipla Ltd. | 6.21% | ₹564.67 Cr | 40,95,054 |
| Lupin Ltd. | 6.16% | ₹559.86 Cr | 27,83,991 |
| Dr. Reddy's Laboratories Ltd. | 6.13% | ₹556.82 Cr | 41,18,506 |
| Apollo Hospitals Enterprise Ltd. | 5.10% | ₹463.62 Cr | 5,48,795 |
| Mankind Pharma Ltd. | 4.40% | ₹399.74 Cr | 16,03,562 |
| Sai Life Sciences Ltd. | 4.04% | ₹366.91 Cr | 23,55,745 |
| Ajanta Pharma Ltd. | 3.53% | ₹320.68 Cr | 9,13,918 |
| Max Healthcare Institute Ltd. | 3.31% | ₹300.84 Cr | 34,98,082 |